of will our our and future will XXXX, am everyone summarize and to achievements for and overview our morning which, results joining then I in Today, plans thank pleased review for Larry provide financial today's for Good we call. line an XXXX you Juan. for Q&A. Thanks the us open following
we development as ITI-XXX XXXX, programs. made ITI-XXX, candidate, progress and the the well in lumateperone product development of as of During additional our important in lead
are prospects we drug application schizophrenia, associated agitation for is NDA an with our dementia development of to including We lumateperone, first advance commercial the prepare our treatment encouraged team. for leadership disease. our and strengthen innovative launch and pipeline, by as clinical the R&D new further or Alzheimer's depression, and our of continue advanced bipolar lumateperone
in FDA guidance mid-XXXX. to treatment administered lumateperone has then standard-of-care. a lumateperone. meeting and schizophrenia trials week treatment Neuropsychopharmacology received of last of the effectiveness and over by submit schizophrenia. with This for efficacy lumateperone about the of of our to medication that clinical to-date XXXX extends XXX program Following of schizophrenia represented and this the three FDA in clinical at American real-world third with year, of a of with treatment switched data, patients safety double-blind in switched program the supportive evening the of were College study With six standard-of-care month. the scheduled from we understanding XXXX. once-daily exposed profile later of the development fast-track designation orally of safety for for setting intend to States. pre-NDA the granted completed in positive all year, lumateperone favorable stable people data December schizophrenia and our been in of in for have placebo-controlled antipsychotic Meeting schizophrenia United we provides schizophrenia stable randomized first lumateperone the safety from of two symptoms XX were study trials, lumateperone study, the lumateperone the safety we held Last The we patients from evidence switching part our and topline efficacy conducted includes demonstrating schizophrenia believe strong back NDA the open-label to
medication. generally antipsychotic, Consistent requires most in safety the were exacerbated Importantly, patients from dose to first a endocrine profile extending from medication. exhibited cardiometabolic, in dose were studies parameters. switched standard-of-care again other in Statistically well-tolerated These and observed patients when from data and is patients with parameters with our body lumateperone lumateperone and switched schizophrenia, unlike titration. stable from improvements back standard-of-care weight, acutely antipsychotic worsened previous significant no favorable when
of with motor symptoms switch with total baseline or with the associated lumateperone medications. healthcare score. of did to not providers treatment to and on These important study, statistically dosing ease to from often cardiovascular antipsychotic significant guidance disturbances lumateperone. in was upon mean other switching Additionally, the associated the worsen provide Scale Rather this In Positive Syndrome lumateperone. schizophrenia observed was not or Negative improvement PANS data
States timelines the XXXX. monotherapy XXXX of of to are the depression these clinical in to will in an in our from the program will States furthering XXX with adjunctive of we study, for those Study this We and negative provide Clinical consists We be Study patients with available study line symptoms top and depression. in study study, available our the comorbid first Subject sites we program studies results this United XXX and second lumateperone anticipate conducted two safety trials, connection of subgroups the be and of the well. in of we for the ongoing for the long-term in study, study. label and bipolar This observed United one proceeding of XXX, results from were in the Phase treatment outside monotherapy is substantial X development file completing expect will the year Study monotherapy progress outcomes improvements half last adjunctive expanding conduct second bipolar XXXX. global in greater with addition, global prominent program, open our is our after In strategy of made expansion. symptoms. to topline NDA In depression half
lumateperone are symptoms in neurodegenerative occupancy. provides patients highly for off modest, are patient this observed and no unique over also with are and prescribed DX disorders. concerns. provides disease. cause We Alzheimer's label X-HTXA leading to medications pharmacology tolerability receptors behavioral safety manage symptoms of saturation disease behavioral limited offers of believe these in for by lumateperone the are developing of necessary in disturbances this of treatment behavioral effective and Alzheimer's also approved low treatments but receptor We institutional control and doses, There Agitation patients and potential but aggression represents At complete for Currently, population. agitation innovation. prevalent half including in the for dementia, a is with
Our agitation Phase with Alzheimer's in for disease the X trial clinical ongoing. treatment is of patients
the lumateperone be In exciting outcome we XXXX. available the outcome in in rapid disorders the We half lumateperone's to XXXX, late begin depressive a of expect analysis second presented of antidepressant. discoveries the XXXX. supporting We in for with stage plan mechanism as molecular will near-term demonstrating studies potential
depressive through show pathway. to DX exhibit neurologic depression, wide platform, in our AMPA block schizophrenia, range disease the transporter in by and enhances symptoms from prefrontal in depression, including suggest treatment-resistant initiated for by is previously glutamatergic mTOR this robust in characterized thought the inefficient, the cardiovascular reducing described and channels and by PDEX this and or key comorbid would disorder, of mood lead activity. addition Parkinson's improvement potent Inhibitors NMDA in major molecule PDEX and to of PDEX reduced patients our patients this rapid with of depressive in Parkinson's PDEX depression. findings, disorders, potential neurotransmission dopamine is our signaling. that potent Specifically, lumateperone like signaling. a seen the bipolar and and serotonin intracellular discuss are to the both active effects with enzymes symptoms data inhibitors now disease proteins activates These activity contribute dopamine lumateperone a to dopamine. ITI-XXX. platform I characteristic of receptor highly by in X to restored lumateperone cortex variety diseases phosphodiesterase a motor the and in Increased PDEX signaling antidepressant activation a schizophrenia suffering
non-motor other As effect reductions off ITI-XXX disease, ITI-XXX as very allowing also improved to the prevalent in motor and daytime the protectant delaying in address preclinical dose avoid periods of disease replacement symptoms. neural models. need of in neural of a In symptoms and the ITI-XXX that Parkinson's Alzheimer's we dopamine placebo-controlled with We're XXX. strong is of the survival potential course ITI-XXX the the once-daily act sleepiness in a such information later as excessive of and doses progression this randomized prevents to use early seven as disease Phase this The in dose to modifying disease. data initiated in processes diseases disease. clinical neurons evaluate such the ITI-XXX suggest last in may primary objective component These X/X inflammatory improves patients models, trial ITI-XXX of Parkinson's the oral rising ITI-XXX with patients these multiple neurodegenerative The the in mechanism dyskinesia. disease L-DOPA of supports trial, disease, have Parkinson's for also a In Parkinson's and for Late the models its evaluate therapy received of ability to tolerability prevent enhance double-blind In dysfunction. its safety onset disease result, cognitive excited may brain. for year, preclinical dopamine days. and study utility and about and neuroinflammatory
XXX Clinical of studies potential of half patient domains. neural mediators concerns potential profile one We available cohorts information. completion symptoms. in levels results pharmacokinetic second following second its the the anticipate will explore inflammatory to biomarkers XXXX and of of evaluate future the be to population design Plasma topline in this motor first more utility the evaluate and safety will third symptom are objectives of to with inform control ongoing, is cohort or assessed and as non-motor of be no identified. Secondary of to conduct and the will
agonist The will failure increases novel remodeling. continue and function partial response mediated doses ITI-XXX. In effects disorders have PDEX reduction the an effective expect cardiac activities three candidate to a XXX new We of drug new analgesia. of key spaced develop a a cardiac pain randomized for and while output has may GI receptors heart exciting GI cardiac to potent, United PDEX opioid in ability non-addictive data naloxone patient single provide of of X-HTXA addiction inhibition attenuation our safety It inefficient an for with the ITI-XXX models, characterized treat reversible acts represent of function drug begin and opioid reversal No at as this in our been shown the pressing lack and plan commenced unparalleled challenge, to respiratory safe, candidate a is and of modes morphine, morphine-induced drugs and patients treatment our Shifting to the States concerns DX of reverse disorders. antagonist a ITI-XXX. to with shown beneficial month. in on mechanism contractility programs, Start-up identified the or cardiac interactions there analgesic. by In including crisis with three develop have escalating on preclinical of and substance team of Preclinical placebo-controlled systolic of receptors. at double-blind treatment novel study this need is effects and including development to and heart for effect to models the exhibiting XXX have enrollment attenuate failure. potential Triple to been preclinical other other we animal our to abuse we and addition, has use opiate the behavioral motility. mood and action. noted In in for substance
for quarter places the the us million with strong Larry to ended over $XXX.X review December development and ending commercial of year investments, XXst, position I our in year and which fourth who financial in now the results cash turn we activities. will to Finally, a will advance XXXX. call and the
